The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: A new marker for gastric cancer risk

Journal of Gastroenterology

Volumn 46, Issue 6, 2011, Pages 736-745

  Kaise, Mitsuru ^a   Miwa, Jun ^b   Tashiro, Jun ^b   Ohmoto, Yasukazu ^c   Morimoto, Shingo ^d   Kato, Masayuki ^e   Urashima, Mitsuyoshi ^e   Ikegami, Masahiro ^e   Tajiri, Hisao ^e  

^a TORANOMON HOSPITAL   (Japan)

^b Shinagawa ku   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d Nomura Hospital   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Gastric cancer; H. pylori; Pepsinogen; Trefoil factor

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; GROWTH FACTOR; INTESTINAL TREFOIL FACTOR; INTESTINAL TREFOIL FACTOR 1; INTESTINAL TREFOIL FACTOR 2; INTESTINAL TREFOIL FACTOR 3; PEPSINOGEN; PEPSINOGEN I; PEPSINOGEN II; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; STOMACH CANCER; VALIDATION PROCESS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPSINOGEN A; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960284255     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0396-8     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74-108.
2. Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer. 1995;60:45-8.
3. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:4873-4. (Pubitemid 44323214)
4. Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol. 1995;362:139-43.
5. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693-7. (Pubitemid 29195918)
6. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141-7. (Pubitemid 39274096)
7. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764-8. (Pubitemid 40732089)
8. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4:721-32. (Pubitemid 37082187)
9. Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE. Are trefoil factors oncogenic? Trends Endocrinol Metab. 2008;19: 74-81. (Pubitemid 351317894)
10. Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 2005;11:6472-8. (Pubitemid 41338984)
11. Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, et al. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology. 2004; 127:582-94. (Pubitemid 39091906)
12. Peterson AJ, Menheniott TR, O'Connor L, Walduck AK, Fox JG, Kawakami K, et al. Helicobacter pylori infection methylates and silences trefoil factor 2 leading to gastric tumor development in mice and humans. Gastroenterology. 2010;139:2005-17.
13. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245-53. (Pubitemid 44846546)
14. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83:204-9. (Pubitemid 12121596)
15. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol. 2006;163: 629-37.
16. Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002;197:582-8.
17. Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, Das M, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut. 2009;58:1451-9.
18. Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 2008;99:768-73.
19. Vestergaard EM, Borre M, Poulsen SS, Nexø E, Tørring N. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 2006; 12(3 Pt 1): 807-12 (Pubitemid 43259861)
20. Vestergaard EM, Nexø E, Tørring N, Borre M, Ørntoft TF, Sørensen KD. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int J Cancer. 2010;127:1857-65.
21. Morson BC, Dawson IMP, Day DW, Jass JR, Price AB, Williams GT, et al. Malignant epithelial tumours. In: Morson and Dawson, editors. Gastrointestinal pathology. 3rd ed. London: Blackwell Scientific Publications; 1990. p. 143-69.
22. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HH. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 2006;55:797-802. (Pubitemid 43764549)